Chemtai Mungo

Chemtai Mungo

Auto-generated profile, based on publicly available information

Chemtai Mungo

Department of Obstetrics and Gynecology, University of North Carolina Chapel Hill

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2024 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
SASharmila Anandasabapathy
Sharmila Anandasabapathy
CAChite Asirwa
Chite Asirwa
SGSurbhi Grover
Surbhi Grover
CMChemtai Mungo
Chemtai Mungo

15 February 2023 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
FRFidel Rubagumya
Fidel Rubagumya
LCLaura Carson
Laura Carson
MMMelinda Mushonga
Melinda Mushonga
AMAchillle Manirakiza
Achillle Manirakiza
GMGad Murenzi
Gad Murenzi
NHNazik Hammad
Nazik Hammad
Disparities in cancer research persist around the world. This is especially true in global health research, where high-income countries (HICs) continue to set global health priorities further creating several imbalances in how research is conducted in low and middle-income countries (LMICs). Cancer research disparities in Africa can be attributed to a vicious cycle of challenges in the research ecosystem ranging from who funds research, where research is conducted, who conducts it, what type of research is conducted and where and how it is disseminated. For example, the funding chasm between HICs and LMICs contributes to inequities and parachutism in cancer research. Breaking the current cancer research model necessitates a thorough examination of why current practices and norms exist and the identification of actionable ways to improve them. The cancer research agenda in Africa should be appropriate for the African nations and continent. Empowering African researchers and ensuring local autonomy are two critical steps in moving cancer research towards this new paradigm.

6 May 2020 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Closed access
PDF file
CMChemtai Mungo
Chemtai Mungo
SISaduma Ibrahim
Saduma Ibrahim
EBElizabeth A. Bukusi
Elizabeth A. Bukusi
HTHong‐Ha M. Truong
Hong‐Ha M. Truong
CCCraig R. Cohen
Craig R. Cohen
MHMegan Huchko
Megan Huchko

15 September 2023 in International Journal of Cancer
Verified
Journal Article
Closed access
CMChemtai Mungo
Chemtai Mungo
COCirilus Ogollah Osongo
Cirilus Ogollah Osongo
JAJeniffer Ambaka
Jeniffer Ambaka
JOJackton Omoto
Jackton Omoto
CCCraig R. Cohen
Craig R. Cohen

1 November 2020 in JCO Global Oncology
Verified
Journal Article
Open access
CMChemtai Mungo
Chemtai Mungo
COCirilus Ogollah Osongo
Cirilus Ogollah Osongo
JAJeniffer Ambaka
Jeniffer Ambaka
MRMagdalene A. Randa
Magdalene A. Randa
JOJackton Omoto
Jackton Omoto
MHMegan Huchko
Megan Huchko
PURPOSE: The WHO now recommends thermal ablation as an alternative to cryotherapy within “screen-and-treat” cervical cancer programs in low- and middle-income countries (LMICs). We conducted a safety and acceptability clinical trial of thermal ablation in a Kenyan Ministry of Health hospital among women living with HIV (WLWH; ClinicalTrials.gov identifier: NCT04191967 ). METHODS: Between August 2019 and February 2020, WLWH age 25-65 years underwent human papillomavirus (HPV) self-collection in western Kenya. HPV-positive women underwent visual inspection with acetic acid, biopsy, and treatment with thermal ablation performed by a nonphysician clinician, if eligible by standard guidelines. A questionnaire was administered after treatment to assess for pain and treatment acceptability. Adverse events (AEs) were evaluated 4-6 weeks after treatment with a standardized grading tool. RESULTS: A total of 293 HPV-positive WLWH underwent thermal ablation in the study period. The mean age was 40.4 years (standard deviation, 8.7 years). After treatment, 15 (5.1%), 231 (78.8%), 42 (14.3%), and 5 (1.8%) reported none, mild, moderate, and severe pain with treatment, respectively. At follow-up, spotting, vaginal discharge, and pelvic pain were reported by 99 (37.8%), 258 (98.5%), and 46 (17.6%), respectively, for a median of 3.3 (interquartile range [IQR], 2-3), 14 (IQR, 7-21), and 7 (IQR, 3-7) days, respectively. Most participants graded their AEs as mild (grade 1): 94 (95.0%) for bleeding, 125 (48.5%) for vaginal discharge, and 37 (80.4%) for pelvic pain. No grade 3 or 4 AEs were reported. The vast majority (99.2%) were satisfied with the treatment and would recommend it to a friend. CONCLUSION: Thermal ablation performed by nonphysicians in the public health sector in Kenya proved safe and highly acceptable in treating HPV-positive WLWH.

2 October 2024 in PLOS Digital Health
Verified
Journal Article
Open access
PDF file
SASyed Rakin Ahmed
Syed Rakin Ahmed
DEDidem Egemen
Didem Egemen
BBBrian Befano
Brian Befano
ARAna Cecilia Rodriguez
Ana Cecilia Rodriguez
JJJose Jeronimo
Jose Jeronimo
MSMark Schiffman
Mark Schiffman
A number of challenges hinder artificial intelligence (AI) models from effective clinical translation. Foremost among these challenges is the lack of generalizability, which is defined as the ability of a model to perform well on datasets that have different characteristics from the training data. We recently investigated the development of an AI pipeline on digital images of the cervix, utilizing a multi-heterogeneous dataset of 9,462 women (17,013 images) and a multi-stage model selection and optimization approach, to generate a diagnostic classifier able to classify images of the cervix into “normal”, “indeterminate” and “precancer/cancer” (denoted as “precancer+”) categories. In this work, we investigate the performance of this multiclass classifier on external data not utilized in training and internal validation, to assess the generalizability of the classifier when moving to new settings. We assessed both the classification performance and repeatability of our classifier model across the two axes of heterogeneity present in our dataset: image capture device and geography, utilizing both out-of-the-box inference and retraining with external data. Our results demonstrate that device-level heterogeneity affects our model performance more than geography-level heterogeneity. Classification performance of our model is strong on images from a new geography without retraining, while incremental retraining with inclusion of images from a new device progressively improves classification performance on that device up to a point of saturation. Repeatability of our model is relatively unaffected by data heterogeneity and remains strong throughout. Our work supports the need for optimized retraining approaches that address data heterogeneity (e.g., when moving to a new device) to facilitate effective use of AI models in new settings.